Malignant neoplasm of lung
FDA Approves Ensartinib for First-Line Treatment of ALK-Positive NSCLC
Ensartinib, ALK-positive NSCLC, FDA approval, lung cancer treatment, Xcovery Holdings
FDA Rejects Subcutaneous Version of J&J’s Lung Cancer Drug Rybrevant Due to Manufacturing Concerns
FDA rejection, J&J, Subcutaneous Rybrevant, Manufacturing issues, Lung cancer drug, Non-small cell lung cancer (NSCLC), Epidermal growth factor receptor (EGFR) mutations
FDA Grants Accelerated Approval to Merus’ Bizengri for NRG1+ Lung and Pancreatic Cancers
Bizengri, NRG1+ cancers, FDA accelerated approval, lung cancer, pancreatic cancer, zenocutuzumab-zbco, Merus N.V.
Roche’s TIGIT Drug Candidate Tiragolumab Fails to Meet Overall Survival Endpoint in Phase 3 Lung Cancer Trial
Roche, TIGIT, tiragolumab, lung cancer, phase 3 trial, SKYSCRAPER-01, overall survival, Keytruda, Tecentriq
FDA Delays Decision on Merus’ Zenocutuzumab for NRG1+ Lung and Pancreatic Cancer
Zenocutuzumab, NRG1+ cancer, FDA delay, Merus, lung cancer, pancreatic cancer, bispecific antibody.
PrognomiQ Secures $34 Million Funding to Enhance Early Lung Cancer Detection with Multi-Omics Technology
PrognomiQ, lung cancer detection, multi-omics technology, early detection test, funding, series D round
Novocure’s Optune Lua Wins FDA Approval for Metastatic Non-Small Cell Lung Cancer Treatment
Novocure, Optune Lua, FDA approval, metastatic non-small cell lung cancer, TTFields, lung cancer treatment, PD-1/PD-L1 inhibitors, docetaxel.
Black Diamond Therapeutics Refocuses on Lung Cancer Drug BDTX-1535 Amid Workforce Reduction
Black Diamond Therapeutics, workforce reduction, lung cancer drug, BDTX-1535, EGFR mutations, Tagrisso, tyrosine kinase inhibitor
FDA Approves Rybrevant for Third NSCLC Indication This Year
Rybrevant, NSCLC, FDA approval, J&J, EGFR mutations, lung cancer treatment
Summit’s Ivonescimab Shows Promising Results Over Keytruda in NSCLC, But Global Validation Needed
NSCLC, Ivonescimab, Keytruda, Bispecific Antibody, Lung Cancer Treatment